Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 3
2005 1
2006 1
2007 1
2009 1
2010 9
2011 2
2012 5
2013 6
2014 6
2015 6
2016 11
2017 19
2018 20
2019 15
2020 14
2021 17
2022 17
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, Stötzer O, Foerster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Kreuzeder J, Guderian G, Fasching PA. Lüftner D, et al. Among authors: tesch h. Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34912. Online ahead of print. Int J Cancer. 2024. PMID: 38447007
Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy.
Krug D, Vladimirova V, Untch M, Kühn T, Schneeweiss A, Denkert C, Ataseven B, Solbach C, Gerber B, Tesch H, Golatta M, Seiler S, Heil J, Nekljudova V, Holtschmidt J, Loibl S. Krug D, et al. Among authors: tesch h. Breast. 2024 Apr;74:103701. doi: 10.1016/j.breast.2024.103701. Epub 2024 Feb 24. Breast. 2024. PMID: 38422624 Free PMC article.
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching PA, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, Fuchs R, Tesch H, Krabisch P, Huober J, Kuemmel S, Brucker S, Janni W, Schneeweiss A, Schuler M, Fehm T, Lüftner D, Quiering C, Voges C, Kreuzeder J, Reinisch M. Fasching PA, et al. Among authors: tesch h. Eur J Cancer. 2024 Feb;198:113480. doi: 10.1016/j.ejca.2023.113480. Epub 2023 Dec 15. Eur J Cancer. 2024. PMID: 38154393 Free article. Clinical Trial.
Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer.
Lux MP, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, Fasching PA, Janni W, Witzel I, Thomssen C, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Kolberg HC, Harbeck N, Bartsch R, Schneeweiss A, Ettl J, Würstlein R, Krug D, Taran FA, Lüftner D, Stickeler E. Lux MP, et al. Among authors: tesch h. Geburtshilfe Frauenheilkd. 2023 Jun 6;83(6):664-672. doi: 10.1055/a-2074-0125. eCollection 2023 Jun. Geburtshilfe Frauenheilkd. 2023. PMID: 37916184 Free PMC article.
Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer.
Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, Fasching PA, Janni W, Witzel I, Thomssen C, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Kolberg HC, Harbeck N, Stickeler E, Bartsch R, Schneeweiss A, Ettl J, Würstlein R, Krug D, Taran FA, Lüftner D. Hartkopf AD, et al. Among authors: tesch h. Geburtshilfe Frauenheilkd. 2023 Jun 6;83(6):653-663. doi: 10.1055/a-2074-0551. eCollection 2023 Jun. Geburtshilfe Frauenheilkd. 2023. PMID: 37916183 Free PMC article.
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Reiser M, Koenigsmann M, Heinrich B, Wehmeyer J, von der Heyde E, Tesch H, Gröschl B, Bachhuber P, Großer S, Pahl HL. Koschmieder S, et al. Among authors: tesch h. Ann Hematol. 2023 Dec;102(12):3383-3399. doi: 10.1007/s00277-023-05458-1. Epub 2023 Oct 4. Ann Hematol. 2023. PMID: 37792065 Free PMC article. Clinical Trial.
Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer Therapies.
Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, Fasching PA, Janni W, Witzel I, Thomssen C, Beierlein M, Belleville E, Untch M, Thill M, Tesch H, Ditsch N, Lux MP, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Harbeck N, Stickeler E, Bartsch R, Schneeweiss A, Ettl J, Krug D, Taran FA, Lüftner D, Würstlein R. Kolberg HC, et al. Among authors: tesch h. Geburtshilfe Frauenheilkd. 2023 Sep 12;83(9):1117-1126. doi: 10.1055/a-2143-8125. eCollection 2023 Sep. Geburtshilfe Frauenheilkd. 2023. PMID: 37706055 Free PMC article.
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients.
Tzschaschel M, Friedl TWP, Schochter F, Schütze S, Polasik A, Fehm T, Pantel K, Schindlbeck C, Schneeweiss A, Schreier J, Tesch H, Lorenz R, Aivazova-Fuchs V, Häberle L, Fasching P, Janni W, Rack BK, Fink V. Tzschaschel M, et al. Among authors: tesch h. Clin Breast Cancer. 2023 Aug;23(6):e345-e353. doi: 10.1016/j.clbc.2023.05.011. Epub 2023 May 23. Clin Breast Cancer. 2023. PMID: 37336651 Clinical Trial.
160 results